Pediatric Cardiology

, Volume 29, Issue 1, pp 210–213 | Cite as

Torsades de Pointes Ventricular Tachycardia in a Pediatric Patient Treated with Fluconazole

  • Jesse J. Esch
  • Michal J. Kantoch
Case Report


Fluconazole is an antifungal medication that has been reported to cause prolongation of the QT interval and Torsades de Pointes (TdP) ventricular tachycardia in adults. We describe the case of an 11-year-old child treated with Fluconazole who developed ventricular arrhythmia culminating in TdP. We discuss the possible roles played by genetic and environmental factors in this child’s rhythm disturbances. After briefly summarizing similar cases from the adult literature, we outline the putative mechanism by which Fluconazole may cause arrhythmia. This case should alert pediatricians to the possible risks of Fluconazole use, especially in the presence of electrolyte abnormalities, diuretic use, therapy with other pro-arrhythmic agents, or suspicion of congenital Long-QT Syndrome.


Fluconazole Torsades de Pointes QT interval Long QT Syndrome 


  1. 1.
    Dorsey ST, Biblo LA (2000) Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 18:227–229PubMedCrossRefGoogle Scholar
  2. 2.
    Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K (2003) Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 60:2479–2483PubMedGoogle Scholar
  3. 3.
    Khazan M, Mathis AS (2002) Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 22:1632–1637PubMedCrossRefGoogle Scholar
  4. 4.
    Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y (2005) Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 144:840–848PubMedCrossRefGoogle Scholar
  5. 5.
    Libersa CC, Brique SA, Motte KB, Caron JF, Guedon-Moreau LM, Humbert L, Vincent A, Devos P, Lhermitte MA (2000) Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 49:373–378PubMedCrossRefGoogle Scholar
  6. 6.
    Priori SG, Naploitano C, Schwartz PJ (1999) Low penetrance in the long-QT syndrome. Circulation 99:529–533PubMedGoogle Scholar
  7. 7.
    Ridley JM, Milnes JT, Duncan RS, McPate MJ, James AF, Witchel HJ, Hancox JC (2006) Inhibition of HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656. FEBS Lett 580:1999–2005PubMedCrossRefGoogle Scholar
  8. 8.
    Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT (2000) Spectrum of mutations in long-QT syndrome genes. Circulation 102:1178–1185PubMedGoogle Scholar
  9. 9.
    Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, Mitsuya H (2006) Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic anemia. Am J Hematol 81:366–369PubMedCrossRefGoogle Scholar
  10. 10.
    Tholakanhalli VN, Potti A, Hanley JF, Merliss AD (2001) Fluconazole-induced torsade de pointes. Ann Pharmacother 35:432–434CrossRefGoogle Scholar
  11. 11.
    Wassman S, Nickenig G, Bohm M (1999) Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med 131:797Google Scholar
  12. 12.
    Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL, Roden DM (2002) Allelic variants in long-QT diseae genes in patients with drug-associated Torsades de Pointes. Circulation 105:1943–1948PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of PediatricsStollery Children’s HospitalEdmontonCanada

Personalised recommendations